Dova Pharmaceuticals, Inc. Announces Proposed Offering of Common Stock

Pharmaceutical Investing

Dova Pharmaceuticals (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. As quoted in the press release: All of the shares in the offering will …

As quoted in the press release:

All of the shares in the offering will be sold by Dova. In addition, Dova expects to grant the underwriters a 30-day option to purchase up to an additional 375,000 shares of common stock at the public offering price, less the underwriting discount. J.P. Morgan Securities LLC, Jefferies LLC and Evercore Group L.L.C. are serving as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Click here to read the full press release.

a pharmaceutical company candidates drug candidates j.p. morgan public offering rare diseases underwritten public offering Pharmaceutical Investing